mhurhangee/ep-ind-claims huggingface dataset:
A volute centrifugal fan with a permanent-magnet brush-less motor system, comprising a volute, an outer rotor motor installed in the volute through a bracket and an impeller externally sleeved on the outer rotor motor; the impeller is positioned in the volute; the impeller is connected with the outer rotor motor; the volute consists of a volute board and side boards on two sides of the volute board; each one of the side boards on both sides is formed with an air inlet; the volute is formed with an air outlet on one side, characterized in that the volute board has an opening positioned above a horizontal plane defined by a center of the air outlet; a bridge arch-type radiator matched with the opening is installed at the position of the opening; radiating ribs of the bridge arch-type radiator are sunk into an air duct formed between the volute and the impeller via the opening; the bridge arch-type radiator is in close fit with the surface of the volute board; the bridge arch-type radiator is installed with a driver matched with the outer rotor motor; the opening is internally provided with fixed ribs which are distributed uniformly, and positioning holes are formed among the fixed ribs; the volute and the impeller form the air duct there-between; the bridge arch-type radiator includes a plurality of radiating rib groups which are disposed at the lower surface thereof; the radiating rib groups pass through the matched positioning holes and are positioned in the air duct; the radiating rib groups consist of a plurality of uniformly distributed radiating ribs; wherein the radius of curvature of an arc formed by each one of the radiating ribs is greater than the radius of curvature of an arc formed by the volute board at the position of the volute board where the driver is installed, after the volute is molded; radiating air channels are formed among the radiating ribs; and the radiating air channels and the air outlet are consistent in the air outflow direction.
An in vitro method for the prognosis of survival of a patient suffering from a solid cancer, comprising the following steps: a) quantifying, in a tumor tissue sample from said patient, the cell density of CD8+ cells, b) quantifying, in a tumor-induced lymphoid structure from said patient, the cell density of DC-LAMP+ dendritic cells, c) comparing cell density values obtained at step a) and b) with predetermined reference values for each type of cells at each location, and d) providing a favorable prognosis of survival time for said patient when the cell density of CD8+ cells and DC-LAMP+ dendritic cells are higher than said predetermined reference values, providing a poor prognosis of survival time for said patient when the cell density of CD8+ cells and DC-LAMP+ dendritic cells are lower than said predetermined reference values, or providing an intermediate prognosis of survival time for said patient when the cell density of one marker is higher than said predetermined reference value and the cell density of the other marker is lower than said predetermined reference value, wherein the method is used in combination with TNM staging classification. a) quantifying, in a tumor tissue sample from said patient, the cell density of CD8+ cells, b) quantifying, in a tumor-induced lymphoid structure from said patient, the cell density of DC-LAMP+ dendritic cells, c) comparing cell density values obtained at step a) and b) with predetermined reference values for each type of cells at each location, and d) providing a favorable prognosis of survival time for said patient when the cell density of CD8+ cells and DC-LAMP+ dendritic cells are higher than said predetermined reference values, providing a poor prognosis of survival time for said patient when the cell density of CD8+ cells and DC-LAMP+ dendritic cells are lower than said predetermined reference values, or providing an intermediate prognosis of survival time for said patient when the cell density of one marker is higher than said predetermined reference value and the cell density of the other marker is lower than said predetermined reference value, wherein the method is used in combination with TNM staging classification.
A ring-shaped roller retaining cage for a caged roller bearing (50, 50A, 50B, 50C, 50D) with a plurality of rollers the ring-shaped roller retaining cage (2, 2A, 2B, 2C) having: pockets defined therein at circumferential locations thereof for accommodating the respective rollers therein, wherein a plated backing layer is applied to one or both of at least an outer diametric surface and opposite end faces of the roller retaining cage (2, 2A, 2B, 2C), which are selected from the entire surface of the roller retaining cage (2, 2A, 2B, 2C); and an Ni • PTFE plated layer is applied to a surface of the plated backing layer, the Ni • PTFE plated layer containing nickel and polytetrafluoroethylene characterized in that the roller retaining cage (2, 2A, 2B, 2C) is carburized and is subsequently tempered and hence has a surface hardness within the range of Hv 450 to Hv 700 and the difference between this surface hardness of the cage and the hardness of the Ni • PTFE plated layer is chosen to be not greater than Hv 200. pockets defined therein at circumferential locations thereof for accommodating the respective rollers therein, wherein a plated backing layer is applied to one or both of at least an outer diametric surface and opposite end faces of the roller retaining cage (2, 2A, 2B, 2C), which are selected from the entire surface of the roller retaining cage (2, 2A, 2B, 2C); and an Ni • PTFE plated layer is applied to a surface of the plated backing layer, the Ni • PTFE plated layer containing nickel and polytetrafluoroethylene characterized in that the roller retaining cage (2, 2A, 2B, 2C) is carburized and is subsequently tempered and hence has a surface hardness within the range of Hv 450 to Hv 700 and the difference between this surface hardness of the cage and the hardness of the Ni • PTFE plated layer is chosen to be not greater than Hv 200.
A crystal form A of a compound I, characterized in that the crystal form A is a monoclinic system and a space group thereof is p2 1, and a single crystal structure being as follows: and a CuKα-X-ray powder diffraction (XRPD) spectrum of the crystal form A comprising diffraction peaks at diffraction angle 2θ positions of: 8.56, 13.40, 15.76, 16.43, 18.38, 18.95, 19.49, 20.62, 20.86, 21.20, 25.99, 26.85, 27.89, 28.48, 29.78, 30.04, 30.84, 31.71, 31.96, 33.95, 34.47, and an error range of 2θ is ±0.2 using CuKα radiation with a wavelength of λ=1.5418Å. characterized in that the crystal form A is a monoclinic system and a space group thereof is p2 1, and a single crystal structure being as follows: and a CuKα-X-ray powder diffraction (XRPD) spectrum of the crystal form A comprising diffraction peaks at diffraction angle 2θ positions of: 8.56, 13.40, 15.76, 16.43, 18.38, 18.95, 19.49, 20.62, 20.86, 21.20, 25.99, 26.85, 27.89, 28.48, 29.78, 30.04, 30.84, 31.71, 31.96, 33.95, 34.47, and an error range of 2θ is ±0.2 using CuKα radiation with a wavelength of λ=1.5418Å.
Puncture sealing agent, comprising: natural rubber latex, an aqueous solution of an adhesive and an antifreezing agent, characterized in that the adhesive is a carbohydrate and in that the puncture sealing agent comprises a solid content resulting from the natural rubber latex in an amount of 21 wt% or less, based on the total weight of the puncture sealing agent, wherein the solid content resulting from the natural rubber is, based on the total weight of the puncture sealing agent, 9 wt% or more. natural rubber latex, an aqueous solution of an adhesive and an antifreezing agent, characterized in that the adhesive is a carbohydrate and in that the puncture sealing agent comprises a solid content resulting from the natural rubber latex in an amount of 21 wt% or less, based on the total weight of the puncture sealing agent, wherein the solid content resulting from the natural rubber is, based on the total weight of the puncture sealing agent, 9 wt% or more.
An endoscopic capsule comprising: - a first imaging system (101, 110, 112) being a white light imaging system, - a second imaging system (102, 110, 112) being a narrowband imaging system, wherein the first imaging system is arranged for obtaining images at a broader spectral range than the second imaging system, and - a processor arranged for image processing, such as a FPGA, wherein the endoscopic capsule is arranged for operating in any one of: - a first mode wherein a frame rate of the first imaging system (101, 110, 112) is higher than a frame rate of the second imaging system (102, 110, 112), and - a second mode wherein the frame rate of the second imaging system is higher than the frame rate of the second imaging system in the first mode, wherein the processor in the first mode is arranged for: - accessing one or more images from the first imaging system (101, 110, 112), - detecting if there is a polyp in the one or more images from the first imaging system (101, 110, 112) by employing a machine learning algorithm, and - switching from the first mode to the second mode if a polyp is detected in the one or more images from the first imaging system (101, 110, 112). - a first imaging system (101, 110, 112) being a white light imaging system, - a second imaging system (102, 110, 112) being a narrowband imaging system, wherein the first imaging system is arranged for obtaining images at a broader spectral range than the second imaging system, and - a processor arranged for image processing, such as a FPGA, - a first mode wherein a frame rate of the first imaging system (101, 110, 112) is higher than a frame rate of the second imaging system (102, 110, 112), and - a second mode wherein the frame rate of the second imaging system is higher than the frame rate of the second imaging system in the first mode, - accessing one or more images from the first imaging system (101, 110, 112), - detecting if there is a polyp in the one or more images from the first imaging system (101, 110, 112) by employing a machine learning algorithm, and - switching from the first mode to the second mode if a polyp is detected in the one or more images from the first imaging system (101, 110, 112).
An optical fiber comprising a glass fiber comprising a core and a cladding; a primary resin layer being in contact with the glass fiber and covering the glass fiber; and a secondary resin layer covering the primary resin layer, wherein a Young's modulus of the primary resin layer is 0.04 MPa or more and 1.0 MPa or less at 23°C ± 2°C, and wherein the secondary resin layer consists of a cured product of a resin composition comprising a base resin containing a urethane (meth)acrylate oligomer, a monomer, and a photopolymerization initiator; and hydrophobic inorganic oxide particles, wherein the monomer is selected from a (meth)acrylate monomer, a (meth)acrylic acid monomer, a maleimide monomer, a (meth)acrylamide monomer, a (meth)acryl succinimide monomer, or a combination thereof, and a content of the inorganic oxide particles is 8% by mass or more and 60% by mass or less based on a total amount of the resin composition, characterized in that the inorganic oxide particles are silicon dioxide. wherein a Young's modulus of the primary resin layer is 0.04 MPa or more and 1.0 MPa or less at 23°C ± 2°C, and wherein the secondary resin layer consists of a cured product of a resin composition comprising a base resin containing a urethane (meth)acrylate oligomer, a monomer, and a photopolymerization initiator; and hydrophobic inorganic oxide particles, wherein the monomer is selected from a (meth)acrylate monomer, a (meth)acrylic acid monomer, a maleimide monomer, a (meth)acrylamide monomer, a (meth)acryl succinimide monomer, or a combination thereof, and a content of the inorganic oxide particles is 8% by mass or more and 60% by mass or less based on a total amount of the resin composition, characterized in that the inorganic oxide particles are silicon dioxide.
A method for obtaining a lipase variant, comprising introducing into a parent lipase, substitutions corresponding to: a) G91A+D96G+T231R+N233R; b) T37R+N39R+G91A+D96G+T231 R+N233R; c) G91A+D96G+G225R+T231R+N233R; or d) G91A+D96G+A150G+T231R+N233R of the mature polypeptide of SEQ ID NO: 2, wherein the variant is a polypeptide comprising an amino acid sequence with at least 90% identity, but less than 100% with the mature polypeptide of SEQ ID NO: 2, has lipase activity, and in comparison with the parent lipase has improved performance in the presence of an organic catalyst selected from the group consisting of organic catalysts having the following formulae: a) b) c) mixtures thereof, wherein each R1 is independently a branched alkyl group containing from 3 to 24 carbons or a linear alkyl group containing from 1 to 24 carbons; and recovering the variant. a) G91A+D96G+T231R+N233R; b) T37R+N39R+G91A+D96G+T231 R+N233R; c) G91A+D96G+G225R+T231R+N233R; or d) G91A+D96G+A150G+T231R+N233R of the mature polypeptide of SEQ ID NO: 2, wherein the variant is a polypeptide comprising an amino acid sequence with at least 90% identity, but less than 100% with the mature polypeptide of SEQ ID NO: 2, has lipase activity, and in comparison with the parent lipase has improved performance in the presence of an organic catalyst selected from the group consisting of organic catalysts having the following formulae: a) b) c) mixtures thereof, wherein each R1 is independently a branched alkyl group containing from 3 to 24 carbons or a linear alkyl group containing from 1 to 24 carbons; and recovering the variant. a) b) c) mixtures thereof,
A locking assembly (70, 170) for a power miter saw of the type which has a base and a table that is rotatably mounted on the base about a center pivot bolt structure defining a center pivot axis, comprising: a pair of oppositely facing arcuate surfaces (62, 64, 206, 208, 234, 236) on said base; a clamp (72, 72', 72", 74, 74', 74", 172, 174) attached to said table for engaging said arcuate surfaces (62, 64, 206, 208, 234, 236) to lock the table from rotating relative to the base; and an actuating mechanism for operating said clamp (72, 72', 72", 74, 74', 74", 172, 174); wherein the pair of oppositely facing arcuate surfaces (62, 64, 206, 208, 234, 236) on said base are spaced from and concentric with said center pivot bolt structure, wherein the clamp (72, 72', 72", 74, 74', 74", 172, 174) locks the table from rotating relative to the base by applying a clamping force to said arcuate surfaces (62, 64, 206, 208, 234, 236) and not to the center pivot bolt structure, wherein said clamp (72, 72', 72", 74, 74', 74", 172, 174) has two clamping surfaces (110, 112, 216, 218, 230, 232), each of which engage one of said arcuate surfaces (62, 64, 206, 208, 234, 236) when said clamp (72, 72', 72", 74, 74', 74", 172, 174) locks the table to the base, wherein said clamping surfaces (110, 112, 216, 218, 230, 232) comprise a first clamping surface (110, 216, 230) on a first jaw (72, 72', 72", 172) and a second clamping surface (112, 218, 232) on a second jaw (74, 74', 74", 174), said first and second jaws (72, 72', 72", 74, 74', 74", 172, 174) being free to float in a generally radial direction relative to said arcuate surfaces (62, 64, 206, 208, 234, 236) and said pivot bolt structure, and said first jaw (72, 72', 72", 172) and said second jaw (74, 74', 74", 174) being slidable relative to one another when said clamping surfaces (110, 112, 216, 218, 230, 232) are not engaged. a pair of oppositely facing arcuate surfaces (62, 64, 206, 208, 234, 236) on said base; a clamp (72, 72', 72", 74, 74', 74", 172, 174) attached to said table for engaging said arcuate surfaces (62, 64, 206, 208, 234, 236) to lock the table from rotating relative to the base; and an actuating mechanism for operating said clamp (72, 72', 72", 74, 74', 74", 172, 174);
Process for obtaining extracts containing methylxanthine derivatives from cakes of plants to the genus Theobroma, wherein the process comprises the following steps: i. Extraction of the cake of plants of the genus Theobroma with an apolar solvent; ii. Filtration of the product obtained in step (i) for forming a defatted cake of plants of the genus Theobroma and an apolar extract; iii. Drying in vacuo the defatted cake obtained in (ii); iv. Hydrolysis of the defatted and dried cake obtained in step (iii) with a strong base for obtaining an hydrolysed extract at a pH of 9.5 to 10.5; v. Separation of the resulting product from step (iv) by centrifugation; vi. Extraction of the aqueous phase; and vii. Complete removal of the solvent contained in the apolar phase obtained in step (vi), to obtain an extract of methylxanthines. i. Extraction of the cake of plants of the genus Theobroma with an apolar solvent; ii. Filtration of the product obtained in step (i) for forming a defatted cake of plants of the genus Theobroma and an apolar extract; iii. Drying in vacuo the defatted cake obtained in (ii); iv. Hydrolysis of the defatted and dried cake obtained in step (iii) with a strong base for obtaining an hydrolysed extract at a pH of 9.5 to 10.5; v. Separation of the resulting product from step (iv) by centrifugation; vi. Extraction of the aqueous phase; and vii. Complete removal of the solvent contained in the apolar phase obtained in step (vi), to obtain an extract of methylxanthines.
An implantable restraint (100, 101, 102) comprising: - an elongated substrate, disposed along a longitudinal axis, the substrate having a first and second surface disposed along transverse planes (600, 700), the substrate further comprising: - an opening, extending through the substrate between the first and second surface, configured to receive in-growth of human or animal tissue after implantation such that a tissue anchor may form; - a pair of facing protrusions (401, 404), disposed between the opening and a distal edge of the substrate, the pair of protrusions (401, 404) being configured to provide an anchor resistance against the tissue anchor to a longitudinal force applied to a proximal section of the substrate; wherein the pair of protrusions (401, 404) are further configured to separate by a distance approximately equal to a transverse extent of the tissue anchor when the longitudinal force exceeds a first predetermined threshold, such that the pair of protrusions (401, 404) moves past the tissue anchor in the direction of the longitudinal force. - an elongated substrate, disposed along a longitudinal axis, the substrate having a first and second surface disposed along transverse planes (600, 700), the substrate further comprising: - an opening, extending through the substrate between the first and second surface, configured to receive in-growth of human or animal tissue after implantation such that a tissue anchor may form; - a pair of facing protrusions (401, 404), disposed between the opening and a distal edge of the substrate, the pair of protrusions (401, 404) being configured to provide an anchor resistance against the tissue anchor to a longitudinal force applied to a proximal section of the substrate;
Milling tool comprising on one hand a basic body having front and rear ends, between which there extend an envelope surface and a centre axis on which the basic body is rotatable, and on the other hand a plurality of single sided and indexable milling inserts having a round basic shape, which individually comprise an upper side, an under side, and a clearance surface that extends between the same and, at least closest to the upper side, converges toward the under side in order to provide a positive cutting geometry of a cutting edge positioned between the clearance surface and a chip surface included in the upper side, which cutting edge includes a reinforcing chamfer surface that is delimited against the clearance surface via an outer boundary line and against the chip surface via an inner boundary line, wherein the milling insert is formed with a plurality of tangentially spaced-apart cutting edges, and wherein the inner boundary line of the chamfer surface diverging from the outer one so as to give the chamfer surface an increasing width in the direction from the first end of the cutting edge toward the second end thereof, the nominal situation of the upper and under sides (9, 10) in the milling insert being determined by upper and lower reference planes (URP, LRP), each one of which extends perpendicular to a centre axis of an imaginary cylinder that circumscribes the periphery of the upper side and thereby defines the round basic shape of the milling insert, the individual milling insert being fixed in a seat formed in a transition between the front end of the basic body and the envelope surface thereof, more precisely by means of, on one hand, a tightening device, and on the other hand co-operating lock means in the seat of the basic body as well as in the milling insert so as to counteract rotation of the last-mentioned one, the milling insert being located in a spatial position that is tipped-in in the basic body and determined by an axial tipping-in angle (α) as well as by a radial one (β), characterized in that the cutting edges of the milling insert individually fall archedly from a first end, situated closest to the upper reference plane of the milling insert, to a lowest point, from which it rises toward a second end.
An alkaline-stable affinity chromatography ligand comprising two or more C domains of Staphylococcus protein A (SpA) attached to a solid support via multipoint attachment, wherein at least one domain comprises: a) an amino acid sequence set forth in SEQ ID NO:11 or an amino acid sequence encoded by the nucleic acid sequence set forth in SEQ ID NO:5; or b) an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:11 or an amino acid sequence having at least 95% identity to the amino acid sequence encoded by the nucleic acid sequence set forth in SEQ ID NO:5; and wherein each C domain comprises a substitution of glycine at position 29 with an amino acid other than alanine or tryptophan and further wherein the ligand retains at least 95% of its binding capacity after 5 hours incubation in 0.5 M NaOH. a) an amino acid sequence set forth in SEQ ID NO:11 or an amino acid sequence encoded by the nucleic acid sequence set forth in SEQ ID NO:5; or b) an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:11 or an amino acid sequence having at least 95% identity to the amino acid sequence encoded by the nucleic acid sequence set forth in SEQ ID NO:5;